报道2例使用双重滤过血浆置换(double filtration plasmapheresis,DFPP)治疗白血病患者严重铁过载，治疗后铁蛋白显著降低且未见严重不良反应。提示DFPP可能是严重铁过载时快速清除铁蛋白的方法，可以用于祛铁药物治疗欠佳或药物不耐受的铁过载患者。
We report two leukemia patients with severe iron overload and successfully treated with double filtration plasmapheresis (DFPP). After the treatment, serum ferritin reduced significantly without any severe complications. We suggest that DFPP is a fast and efficient therapy to remove ferritin, and can be used in severe iron overload patients with poor response or intolerance to drug treatment.
[1]中国医师协会血液科医师分会中华医学会血液学分会.铁过载诊断与治疗的中国专家共识[J].中华血液学杂志, 2011, 32(8):572-574
[2]ITALIA K, COLAH R, GHOSH K.Experimental animal model to study iron overload and iron chelation and review of other such models[J].Blood Cells Mol Dis, 2015, 55(3):194-199
[3]SHENOY N, VALLUMSETLA N, RACHMILEWITZ E, et al.Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome[J].Blood, 2014, 124(6):873-881
[4]HANDA P, MORGAN-STEVENSON V, MALIKEN B D, et al.Iron overload results in hepatic oxidative stress,immune cell activation,and hepatocellular ballooning injury,leading to nonalcoholic steatohepatitis in genetically obese mice[J].Am J Physiol Gastrointest Liver Physiol, 2016, 310(2):G117-G127
[5]PIPERNO A, PELUCCHI S, MARIANI R.Inherited iron overload disorders[J].Transl Gastroenterol Hepatol, 2020, 5(25):-
[6]CAPPELLINI M D, PORTER J, EL-BESHLAWY A, et al.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias[J].Haematologica, 2010, 95(4):557-566
[7]BRAMLAGE C P, ARMSTRONG V W, ZAPF A, et al.Low-density lipoprotein apheresis decreases ferritin,transferrin and vitamin B12,which may cause anemia in serially treated patients[J].Ther Apher Dial, 2010, 14(2):136-142
[8]BASAR R, UZUM A K, CANBAZ B, et al.Therapeutic apheresis for severe hypertriglyceridemia in pregnancy[J].Arch Gynecol Obstet, 2013, 287(5):839-843
[9]BIER-ULRICH A M, HAUBELT H, ANDERS C, et al.The impact of intensive serial plasmapheresis and iron supplementation on iron metabolism and Hb concentration in menstruating women: a prospective randomized placebo-controlled double-blind study[J].Transfusion, 2003, 43(3):405-410
[10]GRADY R W, GALANELLO R, RANDOLPH R E, et al.Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine[J].Haematologica, 2013, 98(1):129-135
[11]De SANCTIS V, SOLIMAN A, YASSIN M.Iron overload and glucose metabolism in subjects with beta-thalassaemia major: an overview[J].Curr Diabetes Rev, 2013, 9(4):332-341
[12]CHUNG W S, LIN C L, LIN C L, et al.Thalassaemia and risk of cancer: a population-based cohort study[J].J Epidemiol Community Health, 2015, 69(11):1066-1070
[13]GIESBRANDT K J, BOLAN C W, SHAPIRO B P, et al.Diffuse diseases of the myocardium: MRI-pathologic review of cardiomyopathies with dilatation[J].AJR Am J Roentgenol, 2013, 200(3):W274-W282
[14]BUJA L M, ROBERTS W C.Iron in the heartEtiology and clinical significance[J].Am J Med, 1971, 51(2):209-221
[15]TAHER A T, CAPPELLINI M D.How I manage medical complications of beta-thalassemia in adults[J].Blood, 2018, 132(17):1781-1791
[16]MEERPOHL J J, SCHELL L K, RUCKER G, et al.Deferasirox for managing iron overload in people with myelodysplastic syndrome[J].Cochrane Database Syst Rev, 2014, 2014(10):D7461-
[17]ALESSANDRINO E P, DELLA P M, BACIGALUPO A, et al.Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study[J].Haematologica, 2010, 95(3):476-484
[18]DAVIS B A, PORTER J B.Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia[J].Blood, 2000, 95(4):1229-1236
[19]MUSALLAM K M, TAHER A T.Iron-chelating therapy for transfusional iron overload[J].N Engl J Med, 2011, 364(15):1476-
[20]LYONS R M, MAREK B J, PALEY C, et al.Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry[J].Leuk Res, 2014, 38(2):149-154
[21]NEUKIRCHEN J, FOX F, KUNDGEN A, et al.Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry[J].Leuk Res, 2012, 36(8):1067-1070
[22]ROSE C, BRECHIGNAC S, VASSILIEF D, et al.Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies)[J].Leuk Res, 2010, 34(7):864-870
[23]YEH J H, CHEN W H, CHIU H C, et al.Clearance studies during subsequent sessions of double filtration plasmapheresis[J].Artif Organs, 2006, 30(2):111-114
[24]YEH J H, CHEN W H, CHIU H C.Complications of double-filtration plasmapheresis[J].Transfusion, 2004, 44(11):1621-1625
